Drug Profile


Alternative Names: DU-28853

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator Solvay
  • Developer Elto Pharma; PsychoGenics; Solvay
  • Class Antidepressants; Antipsychotics; Piperazines; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists; Serotonin 1B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Attention-deficit hyperactivity disorder
  • Phase II Aggression; Drug-induced dyskinesia
  • No development reported Cognition disorders
  • Discontinued Psychotic disorders

Most Recent Events

  • 17 Apr 2017 Eltoprazine licensed to Elto Pharma in (Excluding Asia)
  • 13 Sep 2016 Phase-III clinical trials in Attention-deficit hyperactivity disorder (PO) (Amarantus BioScience pipeline, September 2016)
  • 10 Feb 2016 Eltoprazine receives Orphan Drug status for Drug-induced dyskinesia in patients with Parkinson's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top